A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours

Trial Identifier:	D3614C00003
Sponsor:	AstraZeneca
NCTID::	NCT04958226
Start Date:	October 2021
Primary Completion Date:	February 2023
Study Completion Date:	February 2023
Condition:	Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	English Version
	Spanish (US) Translation

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
US, CO	Aurora, CO, US, 80045
US, NC	Durham, NC, US, 27710
US, OH	Cleveland, OH, US, 44106
US, PA	Pittsburgh, PA, US, 15232
US, TX	Dallas, TX, US, 75251

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company